Objective: Changes in the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in metastatic breast carcinomas are frequently reported. We examined the change in the status of biomarkers in metastatic breast carcinomas. Study Design: This study cohort was composed of 137 metastatic breast carcinomas (58 surgical and 79 cytological specimens) with existing primary tumors during a study period from 2013 to 2015. Results: The overall change rates in metastases were 9, 21 and 6% for ER, PR and HER2, respectively. All changes were from positive in the primary tumor to negative in the metastases. The ER change rate was significantly higher in the cytological than in the surgical metastases. Six of 14 cytological metastases with positive HER2 in primary tumors showed a change in HER2 status, including 5 fluid specimens and 1 fine-needle aspiration (FNA); the other 8 had no change in HER2 status, and included 7 FNAs and 1 fluid specimen. Conclusion: The significant percentage of cases with a change in biomarker status supports the recommendation by the College of American Pathologists to test breast biomarkers in metastases. HER2 status change was mostly identified in fluid specimens; however, the small sample size in our cohort and the fact that HER2 fluorescence in situ hybridization was not performed may warrant further studies.

Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
Greer LT, Rosman M, Mylander WC, et al: Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? J Am Coll Surg 2013;216:239-251.
De Abreu FB, Schwartz GN, Wells WA, Tsongalis GJ: Personalized therapy for breast cancer. Clin Genet 2014;86:62-67.
Ataseven B, Gologan D, Gunesch A, et al: HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care (Basel) 2012;7:465-470.
Rossi S, Basso M, Strippoli A, et al: Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer 2015;15:307-312.
Kuukasjarvi T, Karhu R, Tanner M, et al: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57:1597-1604.
Broom RJ, Tang PA, Simmons C, et al: Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-1562.
Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N: Changes in the ER, PgR, HER2, p53 and ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol 2011;9:131.
Aurilio G, Disalvatore D, Pruneri G, et al: A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014;50:277-289.
Liedtke C, Broglio K, Moulder S, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
Lindstrom LS, Karlsson E, Wilking UM, et al: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-2608.
Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010;21:1254-1261.
Dieci MV, Barbieri E, Piacentini F, et al: Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 2013;24:101-108.
Gancberg D, Di Leo A, Cardoso F, et al: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
Strien L, Leidenius M, von Smitten K, Heikkila P: Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells. Pathol Res Pract 2010;206:253-258.
Santinelli A, Pisa E, Stramazzotti D, Fabris G: HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999-1004.
Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30:593-599.
Shabaik A, Lin G, Peterson M, et al: Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39:328-332.
Kumar SK, Gupta N, Rajwanshi A, Joshi K, Singh G: Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma. Cytopathology 2012;23:181-186.
Domanski AM, Monsef N, Domanski HA, Grabau D, Ferno M: Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology 2013;24:21-25.
Zhang Z, Yuan P, Guo H, et al: Assessment of hormone receptor and human epidermal growth factor receptor 2 status in breast carcinoma using ThinPrep cytology fine-needle aspiration cytology FISH experience from China. Medicine (Baltimore) 2015;94:e981.
Acs B, Szekely N, Szasz AM, et al: Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: a comparative study. Diagn Cytopathol 2016;44:466-471.
Yao ZX, Lu LJ, Wang RJ, et al: Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 2014;31:798.
Theriault RL, Carlson RW, Allred C, et al: Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:753-760.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.